A small-cap share soars 25% on Covid-19 test news. Here’s what I’d do now

Covid-19 tests could generate bundles of cash for companies that make them. But will this small-cap’s shares continue to fly?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

BATM Advanced Communications (LSE: BVC) isn’t a name that would make me immediately think of biotechnology development. But on Tuesday, the firm told us its “Adaltis subsidiary has launched ELISA Serological Test Kits that diagnose if a patient has had Covid-19 by detecting antibodies against it present in their blood.”

The immediate result was a 28% spike in the share price. At the time of writing, the shares have fallen back to a gain of around 20%. But that’s still a pretty nice morning’s profit.

Israel-based BATM describes itself as “a leading provider of real-time technologies for networking solutions and medical laboratory systems.” Its shares had already been climbing since the pandemic lockdown started, on the back of other coronavirus-related business.

The announcement of a tie-up with life sciences company Novamed in March, for the development of a kit to detect the Covid-19 virus itself, provided a boost. And April’s $31m order to produce ventilators won’t do the firm’s balance sheet any harm.

Not just Covid-19

Since the pandemic commenced its assault on the UK stock market, BATM shares are up around 60%. But the company isn’t just a one-hit Covid-19 wonder. No, the BATM share price has five-bagged over the past five years.

My Motley Fool colleague Kevin Godbold was extolling the virtues of this “dynamic small-cap” in August 2018. While Sirius Minerals was a growth darling at the time, he’d spotted how much better BATM shares were doing. I’m sure I’m one of many who wish they’d listened to Kevin back then.

But back to this Covid-19 antibody test. The company has already shipped initial orders to several European countries. And it says it’s “now ramping up production for larger quantities to fulfil further orders received from these customers.”

Why I’m cautious

Covid-19 antibody testing is likely to play a key role in the opening up of lockdown conditions. It identifies those who have been infected and have recovered, and may have immunity. But I’m cautious about piling into BATM shares for several reasons.

One is that the degree of immunity developed after an infection is unknown, and there are fears it might not be very strong. Secondly, a number of companies are making Covid-19 antibody tests. And a lot of them aren’t sufficiently accurate to be of any general use.

Short-term

But my final reason for caution is short-termism. Assuming a Covid-19 vaccine is possible, once one is developed and in widespread use, there’ll be no need for antibody tests. Or for any more emergency supplies of ventilators.

This new test, plus the virus test BATM is working on, might well add handsomely to this year’s profits. And maybe even next year’s. But that could well be the end of it.

I’m not saying don’t buy BATM shares. By all means, get in if you like the look of the company. I just urge any potential investor to base your decision on how you see BATM’s long-term prospects, not just on a short-term Covid-19 boost.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

ISA Individual Savings Account
Investing Articles

How to build a Stocks and Shares ISA with a 6% dividend yield

It’s easy to build an investment portfolio with a high dividend yield today. But investors need to manage risk carefully,…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How risky is switching from cash savings to a Stocks and Shares ISA?

The UK government is making moves to encourage cash savers to consider investing via Stocks and Shares ISAs. But what…

Read more »

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

4,985 shares of this FTSE dividend star pay an income equal to the State Pension!

Zaven Boyrazian calculates how many shares investors would have to buy to generate enough income to match the UK State…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

£500 buys me 407 shares in this 8.2%-yielding income stock!

Got a small lump sum? Zaven Boyrazian explores one underappreciated income stock offering an enormous yield that could be set…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Up 23% this year, is it too late to buy shares in this FTSE 100 compounder?

Having missed Diploma shares at £36 back in April, is a strong trading update with higher guidance a good enough…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

Does this ex-penny stock have the potential to almost double?

This under-the-radar mining stock has doubled in the last 12 months, lifting it out of penny stock territory. But could…

Read more »

A mature adult sitting by a fireplace in a living room at home. She is wearing a yellow cardigan and spectacles.
Investing Articles

£5k in savings? Here’s how that can unlock a £255 monthly second income

Ever wondered how to turn a lump sum of savings into a chunky second income? Zaven Boyrazian explains a simple…

Read more »

British pound data
Investing Articles

Get ready for a US stock market crash?

Experts are waving the red flag on the US stock market and economy, warning of an impending crash. Should investors…

Read more »